Guerbet offers a comprehensive range of imaging products, solutions, and services for Interventional Radiology and Women’s Health to enhance clinical decision-making at each point of the patient journey.
In the UK, Guerbet focuses on the use of Lipiodol within Lymphography and Hysterosalpingography (HSG) in women undergoing fertility workup and other applications.
Guerbet team provides support in multiple educational programmes. To learn more about educational webinars and workshops, please contact your local Guerbet
representative or email firstname.lastname@example.org
Every second, somewhere in the world a patient undergoes an imaging procedure with a Guerbet product.
Advancing in innovative solutions is at the heart of Guerbet's mission and we dedicate 9% of our revenue to R&D. We are focusing on the diagnosis of major diseases (cardiovascular
diseases, cancers, diseases of the central nervous system) and interventional
radiology where hundreds of patents are owned and pending,
It all began with Marcel Guerbet’s discovery of the first iodinated organic contrast medium in 1901. The company was later founded in 1926 by André Guerbet. Since then it has expanded significantly, thanks to the discovery of innovations that have left their mark on medical imaging technologies and the contrast media associated with them. Today, Guerbet
sells a comprehensive range of solutions for diagnostic and interventional
imaging, while continuously investing in innovation and its production
capacities, in addition to a network of subsidiaries and distributors that
ensure a presence in all the principal global markets.
pioneer and a player in the imaging of the future
Although the history of Guerbet dates back to 1901, with the
discovery by Marcel Guerbet of the world’s first
iodinated contrast agent, the official creation of the pharmaceutical company
dates from November 15, 1926. In 1965 it became SA Laboratoires
André Guerbet. From a headcount of 150 at that time,
its staff grew to 1,000 in 1990, 1,500 in 2015 and +2,800 today, following the
acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business in
2015. With this acquisition Guerbet has reached a
critical size in each segment and geographical zone with the ambition of
entering the world’s top three in medical imaging.
Guerbet recently launched a strategic initiative to develop a new
business based on digital technologies and artificial intelligence with two
objectives: first, to improve radiologists' productivity, e.g.
with diagnostic assistance tools, and second, to obtain a tumor
tissue characterization through imaging to better guide treatments or even
eventually replace a biopsy.
From France to International Distribution
From a business essentially focused on France in the early 1960s, Guerbet developed its international distribution network greatly from the 1970s onwards. In 1986, Guerbet
entered the stock market (on the Paris Stock Exchange second market) to bolster
its development. Today, Guerbet is truly an
international group, with 85% of its sales generated outside of France.